臨床検査64巻1号

2020年01月発行

今月の特集1 免疫チェックポイント阻害薬—押さえるべき特徴と注意点

免疫チェックポイント阻害薬の機序と適応

著者： 北野滋久¹

所属機関： ¹がん研究会有明病院先端医療開発センターがん免疫治療開発部

ページ範囲：P.11 - P.19

Point

●近年，複数のがん腫に免疫チェックポイント阻害薬の適応拡大が進んでいる．

●承認されているほとんどのがん腫において，単独療法での奏効割合は15〜40％程度にとどまる．

●免疫チェックポイント阻害薬の耐性機序が明らかになってきている．

●現在，治療成績の向上を目指して，免疫チェックポイント阻害薬を含む複合がん免疫療法（併用療法）の開発が進行中である．

参考文献

1）Brunet JF, Denizot F, Luciani MF, et al：A new member of the immunoglobulin superfamily--CTLA-4. Nature　328：267-270，1987

2）Krummel MF, Allison JP：CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med　182：459-465，1995

3）Leach DR, Krummel MF, Allison JP：Enhancement of antitumor immunity by CTLA-4 blockade. Science　271：1734-1736，1996

4）Ishida Y, Agata Y, Shibahara K, et al：Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J　11：3887-3895，1992

5）Nishimura H, Okazaki T, Tanaka Y, et al：Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science　291：319-322，2001

6）Nishimura H, Nose M, Hiai H, et al：Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity　11：141-151，1999

7）Iwai Y, Ishida M, Tanaka Y, et al：Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A　99：12293-12297，2002

8）Iwai Y, Terawaki S, Honjo T：PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol　17：133-144，2005

9）Freeman GJ, Long AJ, Iwai Y, et al：Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med　192：1027-1034，2000

10）Latchman Y, Wood CR, Chernova T, et al：PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol　2：261-268，2001

11）Zou W, Chen L：Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol　8：467-477，2008

12）北野滋久：免疫チェックポイント阻害剤．岡庭豊（編）：イヤーノート2020 内科・外科編 イヤーノートTOPICS 第9版，メディックメディア，K14，2019

13）Le DT, Uram JN, Wang H, et al：PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med　372：2509-2520，2015

14）Le DT, Durham JN, Smith KN, et al：Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science　357：409-413，2017

15）Ribas A, Wolchok JD：Cancer immunotherapy using checkpoint blockade. Science　359：1350-1355，2018

16）北野滋久，玉田耕治：免疫チェックポイント阻害剤．The Frontiers in Life Sciencesシリーズ　がん免疫療法のメカニズム解明と臨床への展開　がんと免疫（坂口志文，西川博嘉編），南山堂，2015

17）Hodi FS, Chesney J, Pavlick AC, et al：Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol　17：1558-1568，2016

18）Postow MA, Chesney J, Pavlick AC, et al：Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med　372：2006-2017，2015

19）Beatty GL, O'Dwyer PJ, Clark J, et al：First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res　23：3269-3276，2017

20）Jenkins RW, Barbie DA, Flaherty KT：Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer　118：9-16，2018

21）Kroemer G, Galluzzi L, Kepp O, et al：Immunogenic cell death in cancer therapy. Annu Rev Immunol　31：51-72，2013

22）Galluzzi L, Senovilla L, Zitvogel L, et al：The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov　11：215-233，2012

23）Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al：Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med　378：2078-2092，2018

24）Paz-Ares L, Luft A, Vicente D, et al：Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med　379：2040-2051，2018

25）Socinski MA, Jotte RM, Cappuzzo F, et al：Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med　378：2288-2301，2018

26）Papadimitrakopoulou V, Cobo M, Bordoni R, et al：OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab+Carboplatin/Cisplatin+Pemetrexed in Stage IV Non-Squamous NSCLC. J Thorac Oncol　13(Suppl)：S332-S333，2018

27）Hellmann MD, Ciuleanu TE, Pluzanski A, et al：Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med　378：2093-2104，2018

28）Horn L, Mansfield AS, Szczęsna A, et al：First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med　379：2220-2229，2018

29）Wada J, Suzuki H, Fuchino R, et al：The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res　29：881-888，2009

30）Osada T, Chong G, Tansik R, et al：The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother　57：1115-1124，2008

31）Manzoni M, Rovati B, Ronzoni M, et al：Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology　79：187-196，2010

32）Shrimali RK, Yu Z, Theoret MR, et al：Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res　70：6171-6180，2010

33）Galluzzi L, Buqué A, Kepp O, et al：Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol　17：97-111，2017

34）Mackenzie KJ, Carroll P, Martin CA, et al：cGAS surveillance of micronuclei links genome instability to innate immunity. Nature　548：461-465，2017

35）Deng L, Liang H, Xu M, et al：STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity　41：843-852，2014

36）Cai X, Chiu YH, Chen ZJ：The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell　54：289-296，2014

37）Vanpouille-Box C, Alard A, Aryankalayil MJ, et al：DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun　8：15618，2017

38）Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, et al：Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol　39：644-655，2018

39）Postow MA, Callahan MK, Barker CA, et al：Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med　366：925-931，2012

40）Antonia SJ, Villegas A, Daniel D, et al：Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med　377：1919-1929，2017